Deals
Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Crohn’s & Colitis Foundation’s IBD Ventures award supports development of Thetis’ novel first-in-class Resolvin oral therapy (TP-317) for treatment of ulcerative colitis and Crohn’s disease
A consortium jointly led by Astorg and Cinven announces that it has signed an agreement to acquire LGC, a global leader in the Life Sciences Tools sector.
Series A round lead investors NordicNinja and Industrifonden to support Combinostics as they scale to US and Asia
Vivoryon Therapeutics AG, will publish its third quarter financial results and a business update for the period ended September 30, 2019 on Thursday, November 28, 2019, in the form of an interim management report.
With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.
Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, announced the establishment of an equity line facility to enhance the Company’s financial flexibility and improve liquidity for shareholders.
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
Epigenomics AG announced its financial results for the first nine months of 2019.
Amarantus Bioscience Holdings, Inc. released a letter to its shareholders following the announcement of the binding term sheet to license the Company’s therapeutics subsidiaries’ technologies to Emerald Organic Products, an emerging CBD-focused health sciences company, and other recent events
Recipharm AB and Consort Medical plc have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort, a leading global drug delivery and device company and integrated contract development and manufacturing organisation